Amgen's multiple myeloma drug falls short in late stage study
September 27, 2016 at 05:13 AM EDT
Sept 27 (Reuters) - Amgen Inc said on Tuesday its cancer drug Kyprolis failed to meet the main goal of a late-stage study against Takeda Pharmaceutical Co Ltd's Velcade for treating newly diagnosed multiple myeloma.
